Atlas FDA

VENTANA PD-L1 (SP263) ASSAY

FDA premarket approval P160046 · decided 2017-05-01

Approval details

PMA number
P160046
Trade name
VENTANA PD-L1 (SP263) ASSAY
Generic name
Immunohistochemistry assay, antibody, programmed death-ligand 1
Applicant
Ventana Medical Systems, Inc.
Date received
2016-10-20
Decision date
2017-05-01
Days to decision
193 days
Decision code
APPR
Product code
PLS
Advisory committee
Pathology
Expedited review
No
Location
Tucson, AZ
Statement
Approval for the VENTANA PD-L1 (SP263) Assay is a qualitative immunohistochemical assay using rabbit monoclonal anti-PD-L1 clone SP263 intended for use in the assessment of the PD-L1 protein in formalin-fixed, paraffin-embedded (FFPE) urothelial carcinoma tissue stained with OptiView DAB IHC Detection Kit on a VENTANA BenchMark ULTRA instrument.PD-L1 status is determined by the percentage of tumor cells with any membrane staining above background or by the percentage of tumor-associated immune c

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
Roche Digital Pathology Dx (K242783)Ventana Medical Systems, Inc.2024-12-17
VENTANA Kappa and Lambda Dual ISH mRNA Probe Cocktail (08507023001) (DEN240025)Ventana Medical Systems, Inc.2024-12-05
Roche Digital Pathology Dx (VENTANA DP 200) (K232879)Ventana Medical Systems, Inc.2024-06-14
CINtec Histology (K212176)Ventana Medical Systems, Inc.2021-12-10
VENTANA CD30 (Ber-H2) RxDx Assay (K172471)Ventana Medical Systems, Inc.2018-05-08
CINtec Histology (50 tests), CINtec Histology (250 tests) (DEN160019)Ventana Medical Systems, Inc.2017-03-04
Virtuoso System for IHC PR (1E2) using iScan HT (K142965)Ventana Medical Systems, Inc.2015-07-16
VIRTUOSO SYSTEM FOR IHC ER (SP1) WITH BENCHMARK ULTRA STAINER (K140465)Ventana Medical Systems, Inc.2014-03-20